PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 29435010-6 2018 Additionally, the exposure of OS-RC-2 cells to CQ and sunitinib resulted in the inhibition of AKT, tuberous sclerosis complex 2, mechanistic target of rapamycin and p70 ribosomal S6 kinase, which are associated with cell proliferation. Sunitinib 54-63 AKT serine/threonine kinase 1 Homo sapiens 94-97 16916320-0 2006 Effect of SU11248 on gastrointestinal stromal tumor-T1 cells: enhancement of growth inhibition via inhibition of 3-kinase/Akt/mammalian target of rapamycin signaling. Sunitinib 10-17 AKT serine/threonine kinase 1 Homo sapiens 122-125 16916320-6 2006 Western blot analyses found that SU11248 blocked autophosphorylation of c-KIT in association with inhibition of its downstream effectors, including Akt and extracellular signal-regulated kinase, but not signal transducers and activators of transcription. Sunitinib 33-40 AKT serine/threonine kinase 1 Homo sapiens 148-151 16916320-7 2006 Interestingly, when phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin signaling was blocked simultaneously by either LY294002 or rapamycin, growth inhibition mediated by SU11248 was potentiated. Sunitinib 184-191 AKT serine/threonine kinase 1 Homo sapiens 50-53 34765076-5 2021 We found that S6 activation was more common in poor risk NC-RCC tumors and S6/Akt activation was associated with worse PFS and OS outcomes with both everolimus and sunitinib, while c-kit was commonly expressed in chromophobe tumors and associated with improved outcomes with both agents. Sunitinib 164-173 AKT serine/threonine kinase 1 Homo sapiens 78-81 35216667-6 2022 Functionally, re-expressing wild-type FH or PTEN C211S phenocopies an AKT inhibitor in suppressing tumor growth and sensitizing PRCC2 to sunitinib. Sunitinib 137-146 AKT serine/threonine kinase 1 Homo sapiens 70-73 35318312-0 2022 Single-cell RNA-sequencing analysis reveals MYH9 promotes renal cell carcinoma development and sunitinib resistance via AKT signaling pathway. Sunitinib 95-104 AKT serine/threonine kinase 1 Homo sapiens 120-123 35318312-9 2022 Furthermore, MYH9/AKT axis determined the responses of ccRCC cells to sunitinib treatment and might serve as a biomarker for sunitinib benefits in ccRCC patients. Sunitinib 70-79 AKT serine/threonine kinase 1 Homo sapiens 18-21 35318312-9 2022 Furthermore, MYH9/AKT axis determined the responses of ccRCC cells to sunitinib treatment and might serve as a biomarker for sunitinib benefits in ccRCC patients. Sunitinib 125-134 AKT serine/threonine kinase 1 Homo sapiens 18-21 33893075-6 2021 Phosphoproteomic signatures, including phosphoinositide 3-kinase and protein kinase B (PI3K-AKT) as well as other pathways, were up-regulated in sunitinib-resistant cells but application of G-1 reversed this effect. Sunitinib 145-154 AKT serine/threonine kinase 1 Homo sapiens 92-95 30821250-8 2019 Analysis of post-receptor pathways controlling proliferation and migration of HUVECs showed suppression of phosphorylated PI3K/Akt and ERK1/2 after exposure to sunitinib but not to 3PO in 10 microM concentration. Sunitinib 160-169 AKT serine/threonine kinase 1 Homo sapiens 127-130 30281919-8 2019 EMT course and AKT/GSK-3beta signal pathway both in vitro and in vivo in sunitinib environment was suppressed to varying degrees via NT5E inhibition. Sunitinib 73-82 AKT serine/threonine kinase 1 Homo sapiens 15-18 30369518-15 2018 And we found that 786-O RCC cells secrete high IL-6 levels after low dose stimulation with the TKIs sorafenib, sunitinib and pazopanib, inducing activation of AKT-mTOR pathway, NFkappaB, HIF-2alpha and VEGF expression. Sunitinib 111-120 AKT serine/threonine kinase 1 Homo sapiens 159-162 28327411-2 2017 Investigation of Gas6-mediated Axl signaling in CCRCC and endothelial cells reveals a Sunitinib resistant Gas6-Axl signaling that is sustained and enhanced and specifically triggers downstream AKT and PRAS40 activation in an intensified manner. Sunitinib 86-95 AKT serine/threonine kinase 1 Homo sapiens 193-196 28898759-8 2017 In addition, CONPs downregulate the expression of AXL, MET, AKT, and ERK to recover sunitinib responsiveness in RCC cells with sunitinib resistance (SR) and may therefore facilitate the development of promising new pathways to treat patients with acquired SRRCC. Sunitinib 84-93 AKT serine/threonine kinase 1 Homo sapiens 60-63 28903416-7 2017 786-O RCC cells secrete high IL-6 levels after low dose stimulation with the TKIs sorafenib, sunitinib and pazopanib, inducing activation of AKT-mTOR pathway, NFkappaB, HIF-2alpha and VEGF expression. Sunitinib 93-102 AKT serine/threonine kinase 1 Homo sapiens 141-144 25917740-0 2015 Enhanced Sensitivity to Sunitinib by Inhibition of Akt1 Expression in Human Castration-resistant Prostate Cancer PC3 Cells Both In Vitro and In Vivo. Sunitinib 24-33 AKT serine/threonine kinase 1 Homo sapiens 51-55 29263493-0 2016 [Sunitinib induces autophagy via suppressing Akt/mTOR pathway in renal cell carcinoma]. Sunitinib 1-10 AKT serine/threonine kinase 1 Homo sapiens 45-48 29263493-14 2016 The rapamycin (mTOR inhibitor) or knocking down Akt subunits could change the sunitinib-induced LC3 -II accumulation, whereas overexpression of Akt subunits decreased the autophagic flux, indicating that Akt/mTOR was the target of sunitinib in autophagy. Sunitinib 78-87 AKT serine/threonine kinase 1 Homo sapiens 48-51 27538132-0 2016 [Sunitinib induces autophagy via suppressing Akt/mTOR pathway in renal cell carcinoma]. Sunitinib 1-10 AKT serine/threonine kinase 1 Homo sapiens 45-48 27538132-14 2016 The rapamycin (mTOR inhibitor) or knocking down Akt subunits could change the sunitinib-induced LC3 -II accumulation, whereas overexpression of Akt subunits decreased the autophagic flux, indicating that Akt/mTOR was the target of sunitinib in autophagy. Sunitinib 78-87 AKT serine/threonine kinase 1 Homo sapiens 48-51 27538132-15 2016 CONCLUSION: Sunitinib induced autophagy via suppressing Akt/mTOR pathway, and the autophagy was involved in apopotosis. Sunitinib 12-21 AKT serine/threonine kinase 1 Homo sapiens 56-59 25917740-5 2015 However, compared with PC3/C, PC3/sh-Akt1 showed a significantly higher sensitivity to sunitinib, accompanying impaired phosphorylation of p44/42 mitogen-activated protein kinase, downregulation of Bcl-2, and upregulation of Bax. Sunitinib 87-96 AKT serine/threonine kinase 1 Homo sapiens 37-41 25917740-6 2015 In addition, treatment with sunitinib significantly suppressed the migration ability of PC3/sh-Akt1 compared with that of PC3/C. Sunitinib 28-37 AKT serine/threonine kinase 1 Homo sapiens 95-99 29263493-15 2016 CONCLUSION: Sunitinib induced autophagy via suppressing Akt/mTOR pathway, and the autophagy was involved in apopotosis. Sunitinib 12-21 AKT serine/threonine kinase 1 Homo sapiens 56-59 27016208-7 2016 We found that sunitinib enhances TRAIL-induced G0/G1-phase cell cycle arrest and blocks TRAIL-triggered activation of AKT as the underlying mechanism. Sunitinib 14-23 AKT serine/threonine kinase 1 Homo sapiens 118-121 25917740-1 2015 OBJECTIVE: To investigate whether antitumor activity of sunitinib is enhanced by silencing Akt1 in a human castration-resistant prostate cancer PC3 model. Sunitinib 56-65 AKT serine/threonine kinase 1 Homo sapiens 91-95 25917740-3 2015 Changes in various phenotypes of PC3/sh-Akt1 after treatment with sunitinib were compared with those of PC3 transfected with control vector alone (PC3/C) both in vitro and in vivo. Sunitinib 66-75 AKT serine/threonine kinase 1 Homo sapiens 40-44 24018642-6 2014 Combination of rapamycin with sunitinib resulted in enhanced cell cycle arrest in G1 phase, which was accompanied with enhanced suppression of mTOR signaling and disruption of the negative feedback loop that activate AKT upon mTORC1 inhibition. Sunitinib 30-39 AKT serine/threonine kinase 1 Homo sapiens 217-220 25637219-8 2015 The combination of sunitinib with a specific AKT inhibitor reverted the resistance of AXL-silenced cells to sunitinib. Sunitinib 19-28 AKT serine/threonine kinase 1 Homo sapiens 45-48 25637219-8 2015 The combination of sunitinib with a specific AKT inhibitor reverted the resistance of AXL-silenced cells to sunitinib. Sunitinib 108-117 AKT serine/threonine kinase 1 Homo sapiens 45-48 25637219-10 2015 Moreover, it indicates that combining sunitinib therapy with AKT pathway inhibitors could overcome sunitinib resistance. Sunitinib 99-108 AKT serine/threonine kinase 1 Homo sapiens 61-64 25993161-7 2015 For recurrent and aggressive tumors, inhibitors of the vascular endothelial growth factor (VEGF) pathway, such as vatalinib, bevacizumab, and sunitinib, showed signs of activity in small, uncontrolled studies, and prospective clinical studies will test the efficacy of the tetrahydroisoquinoline trabectedin and of SMO and AKT1 inhibitors. Sunitinib 142-151 AKT serine/threonine kinase 1 Homo sapiens 323-327 26788996-5 2015 Sunitinib inhibited PDGF-stimulated proliferation, migration, phosphorylation of MAPK and PI3K/Akt proteins and changes in the expression of cell-cycle regulatory proteins in vascular smooth-muscle cells as well as VEGF-stimulated endothelial cell proliferation in vitro. Sunitinib 0-9 AKT serine/threonine kinase 1 Homo sapiens 95-98 25130811-9 2014 Western blot detection showed that the expression of p-Akt protein in K562 cells decreased in dose-and time-dependent manner after SU11248 treatment, but the expression of Akt was not significantly changed. Sunitinib 131-138 AKT serine/threonine kinase 1 Homo sapiens 55-58 25130811-10 2014 It is concluded that SU11248 can inhibit the growth of K562 cells efficiently through inducing apoptosis, its mechanism may be closely relate with the expression down-regulation of C-MYC, hTERT, BCR-ABL and the inhibition of Akt phosphorylation. Sunitinib 21-28 AKT serine/threonine kinase 1 Homo sapiens 225-228 24045439-8 2014 Similarly, sunitinib, a small-molecule inhibitor of RET, blocked GDNF-mediated activation of ERK and AKT. Sunitinib 11-20 AKT serine/threonine kinase 1 Homo sapiens 101-104 25109654-6 2014 The results demonstrated that sunitinib was able to reverse the multidrug resistance of A549/DDP lung cancer cells, which was possibly associated with the downregulation of multidrug resistance-associated gene expression and the inhibition of AKT and ERK phosphorylation. Sunitinib 30-39 AKT serine/threonine kinase 1 Homo sapiens 243-246 24974736-7 2014 Sunitinib or LY294002, but not erlotinib, significantly inhibited the platelet-induced proliferation of osteosarcoma cells, indicating that PDGF released from platelets plays an important role in the proliferation of osteosarcomas by activating the PDGFR and then Akt. Sunitinib 0-9 AKT serine/threonine kinase 1 Homo sapiens 264-267 22338018-4 2012 And, recent phase III studies showed both everolimus and sunitinib improved progression-free survival in pancreatic NETs, validating the phosphoinositide 3-kinase/Akt/mTOR pathway and angiogenesis as important targets for further advances. Sunitinib 57-66 AKT serine/threonine kinase 1 Homo sapiens 163-166 23969186-0 2013 Antiproliferative and proapoptotic activity of sunitinib on endothelial and anaplastic thyroid cancer cells via inhibition of Akt and ERK1/2 phosphorylation and by down-regulation of cyclin-D1. Sunitinib 47-56 AKT serine/threonine kinase 1 Homo sapiens 126-129 23969186-10 2013 Phospho-epidermal growth factor receptor, ERK1/2, and Akt phosphorylation was significantly inhibited by sunitinib treatment in endothelial and cancer cells, and cyclin-D1 mRNA and protein expression was inhibited. Sunitinib 105-114 AKT serine/threonine kinase 1 Homo sapiens 54-57 23969186-12 2013 CONCLUSIONS: Sunitinib is active in vitro and in vivo against activated endothelial and ATC cells via the inhibition of Akt and ERK1/2 phosphorylation and through the down-regulation of cyclin-D1. Sunitinib 13-22 AKT serine/threonine kinase 1 Homo sapiens 120-123 22733151-10 2012 In vitro cell line study by immunowestern blotting found that sunitinib malate had an inhibitory effect on the PDGFA pathway by decreasing p-PDGFRA, AKT, and p-AKT expression. Sunitinib 62-78 AKT serine/threonine kinase 1 Homo sapiens 149-152 22733151-10 2012 In vitro cell line study by immunowestern blotting found that sunitinib malate had an inhibitory effect on the PDGFA pathway by decreasing p-PDGFRA, AKT, and p-AKT expression. Sunitinib 62-78 AKT serine/threonine kinase 1 Homo sapiens 160-163 22532600-0 2012 Modulation of Akt/mTOR signaling overcomes sunitinib resistance in renal and prostate cancer cells. Sunitinib 43-52 AKT serine/threonine kinase 1 Homo sapiens 14-17 23812726-7 2013 The inhibition of kinase activation using multi-targeted kinase inhibitors, sorafenib and sunitinib led to significant cell growth inhibition and apoptosis induction via suppression of Erk1/2 and Akt activation, whereas drugs with specificity to a single kinase showed less potency. Sunitinib 90-99 AKT serine/threonine kinase 1 Homo sapiens 196-199 21445973-5 2012 Examination of intracellular signaling found that Akt/ mammalian target of rapamycin (mTOR) signaling remained activated in GIST-T1R but not in parental GIST-T1 cells, after exposure of these cells to sunitinib, as measured by immunoblotting. Sunitinib 201-210 AKT serine/threonine kinase 1 Homo sapiens 50-53 21445974-0 2012 Inhibition of activated receptor tyrosine kinases by Sunitinib induces growth arrest and sensitizes melanoma cells to Bortezomib by blocking Akt pathway. Sunitinib 53-62 AKT serine/threonine kinase 1 Homo sapiens 141-144 21445974-6 2012 Moreover, the two metastatic melanoma cell lines harbored an activated receptor (PDGFRalpha and VEGFR, respectively), and Sunitinib suppressed the phosphorylation of the RTKs and their downstream targets Akt and ribosomal protein S6, in these two cell lines. Sunitinib 122-131 AKT serine/threonine kinase 1 Homo sapiens 204-207 21445974-10 2012 Moreover, LY294002, a PI3K inhibitor, sensitized melanoma cells to Bortezomib treatment, suggesting that downregulation of phospho-Akt by Sunitinib mediates the synergy obtained by Bortezomib + Sunitinib cotreatment. Sunitinib 138-147 AKT serine/threonine kinase 1 Homo sapiens 131-134 21445974-10 2012 Moreover, LY294002, a PI3K inhibitor, sensitized melanoma cells to Bortezomib treatment, suggesting that downregulation of phospho-Akt by Sunitinib mediates the synergy obtained by Bortezomib + Sunitinib cotreatment. Sunitinib 194-203 AKT serine/threonine kinase 1 Homo sapiens 131-134 21693010-8 2011 RESULTS: First, in human LECs, sunitinib blocked both VEGFR-2 and VEGFR-3 phosphorylation induced by VEGF-C or VEGF-D, and abrogated the activation of the downstream molecules extracellular signal-regulated kinase 1/2 (ERK1/2) and Akt. Sunitinib 31-40 AKT serine/threonine kinase 1 Homo sapiens 231-234 23650573-4 2012 However, the phosphorylations of receptor tyrosine, Akt and ERK were significant inhibited by sunitinib. Sunitinib 94-103 AKT serine/threonine kinase 1 Homo sapiens 52-55 21344032-9 2011 Sunitinib suppressed the expression of cyclin B1, p-Akt, and t-Akt while augmenting the expression of cyclin D and pro-apoptotic Bax and Bad in HTB5 cells. Sunitinib 0-9 AKT serine/threonine kinase 1 Homo sapiens 52-55 21187670-10 2011 The activity of PI3K/Akt signal pathway was inhibited, which could be the potential mechanisms that account for the enhanced radiation response induced by sunitinib. Sunitinib 155-164 AKT serine/threonine kinase 1 Homo sapiens 21-24 21344032-9 2011 Sunitinib suppressed the expression of cyclin B1, p-Akt, and t-Akt while augmenting the expression of cyclin D and pro-apoptotic Bax and Bad in HTB5 cells. Sunitinib 0-9 AKT serine/threonine kinase 1 Homo sapiens 63-66 19467916-5 2009 We discuss how the cross-talk between major downstream signaling pathways, such as PI3K/PTEN/Akt/mTOR, RAS/Raf/MEK/ERK, and Jak/STAT, can be exploited for therapeutic purposes by targeting key signaling molecules with selective inhibitors, such as mTOR inhibitors, HSP90 inhibitors, or farnesyltransferase inhibitors, and identifying those agents with the ability to positively combine with inhibitors of FLT3, such as PKC412 and sunitinib. Sunitinib 430-439 AKT serine/threonine kinase 1 Homo sapiens 93-96 20053726-10 2010 Expression of a constitutively activated STAT3 mutant or myristoylated AKT partially blocked the effects of sunitinib in these tumor cells. Sunitinib 108-117 AKT serine/threonine kinase 1 Homo sapiens 71-74 20053726-0 2010 Sunitinib induces apoptosis and growth arrest of medulloblastoma tumor cells by inhibiting STAT3 and AKT signaling pathways. Sunitinib 0-9 AKT serine/threonine kinase 1 Homo sapiens 101-104 20053726-9 2010 Loss of phosphorylated AKT after sunitinib treatment was accompanied by decreased phosphorylation of downstream proteins glycogen synthase kinase-3beta and mammalian target of rapamycin. Sunitinib 33-42 AKT serine/threonine kinase 1 Homo sapiens 23-26 18514780-7 2008 RESULTS: SU11248 attenuated radiation-induced phosphorylation of Akt and ERK at 0, 5, 15, and 30 min. Sunitinib 9-16 AKT serine/threonine kinase 1 Homo sapiens 65-68